Adalimumab (Humira), of Abbvie, is the biosimilar medicine that provides the most savings to the National system of health. According to the latest report from the Spanish Association of Biosimilars (Biosim) "Analysis of the budgetary impact of biosimilar medicines in the Spanish National Health System (2009-2022)", this drug could generate savings this year of approximately 270 millones de euros.
